---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla
run_number: 2
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 201
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 201, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation: Claim File Review
You are currently facing a "false positive" crisis. Your commercial metrics (bookings/renewals) are being inflated by temporary pricing and sales narratives, while your usage metrics are skewed by managers performing audits rather than adjusters performing work.

The Claim File Review is the only option that penetrates the "entangled" evidence to find the ground truth: **Does DraftPath actually solve a problem for the end-user, or is it merely a management reporting tool?**

By analyzing whether suggestions were accepted, overridden, or "impossible to explain," you will determine if the product has a fundamental utility gap (the health-liability issue) or an enablement gap. This allows you to enter the next budget cycle with a factual basis for whether to pivot, polish, or persevere, rather than guessing based on lagged churn data or manipulated sales cycles.

### The Strongest Reason Against It
**It is the slowest path to a "commercial" answer.** Unlike the Commercial Cleanroom, which tests willingness to pay, or the Usage Quality Sprint, which tracks behavioral trends in real-time, a file review is manual, qualitative, and small-sample. It does not provide the board with a "revenue forecast" or a "growth multiplier"; it provides a product diagnostic. In a high-pressure budget window, the CEO may view this as "academic" compared to the immediate revenue signals of a Cleanroom.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in health-liability is a fringe edge case (affecting <5% of total volume) and the primary driver of current growth is purely price-sensitivity. If the product is "good enough" and the only real risk is that Sales is over-promising a roadmap to close deals, you no longer have a product problem—you have a pricing and positioning problem. In that case, validating the price floor is more urgent than auditing the claim files.
